Skip to content
stoqly

Addus HomeCare

ADUS Nasdaq Health Care Services Financials FY2016–FY2025

Addus HomeCare's revenue rose 23.2% to $1.4 billion in fiscal 2025. Its operating margin was 9.7%, up from 8.9% a year earlier. Free cash flow was $104 million, down 6.0%. The diluted share count rose 5.8%.

Last close · Oct 23, 2026

$121.81

0.7%
Value it Compare
Revenue Total sales reported in the income statement.
$1.4B
23.2% vs prior year
Operating margin Operating income as a share of revenue.
9.7%
0.8 pts
Net income Profit after all expenses, interest and tax.
$95.9M
30.3%
Free cash flow Cash from operations minus capital spending.
$104M
6.0%
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
9.4%
1.2 pts
Market cap Last close times the latest diluted share count, so it is approximate.
$2.3B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
21.3x
On $5.71 EPS (TTM)

What Addus HomeCare does

No business description yet.

Legal name
Addus HomeCare Corp
Fiscal year ends
December 31, 2025
Latest annual report
—
Accession · CIK
0001437749-26-005352
0001468328

Revenue and margins

Addus HomeCare had $1.4B of revenue in fiscal 2025, up 23.2% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

From fiscal 2016 to 2025, diluted EPS grew 19.3% a year. Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $104M in fiscal 2025, 7.3% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Addus HomeCare returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 5.8%.

Dividends and buybacks
Dividends Buybacks
Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Value Addus HomeCare yourself

Change the assumptions and see what they imply per share. These are models, not forecasts or price targets — the answer depends entirely on what you put in.

Discounted cash flow

Value per share

—

Adds net cash of −$39.4M and divides by 18.4M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.

Earnings multiple

Value per share

—

Reference multiples: today 21.3x · peers 37.3x · sector 28.4x.

Balance sheet

Cash, debt and the ratios that show how comfortably Addus HomeCare can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $169M$80.0M$64.8M$98.9M$81.6M
Debt incl. finance leases $221M$132M$124M$218M$121M
Net debt / EBITDA 0.7x0.6x0.6x1.0x0.3x
Debt / equity 0.4x0.2x0.2x0.2x0.1x
Interest coverage 11.4x7.7x8.2x13.3x10.2x
Current ratio 2.8x1.7x1.4x1.7x1.8x
Quick ratio 2.8x1.7x1.4x1.7x1.8x
Total assets $948M$938M$1.0B$1.4B$1.4B
Total liabilities $373M$305M$318M$442M$352M
Shareholders' equity $574M$634M$707M$971M$1.1B
Net debt (− = net cash) $52.0M$51.8M$59.3M$120M$39.4M

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.6M

11 insiders

Of sales under plans

93%

$0.6M

DateInsiderTradeSharesPriceValueFiling
Jun 22, 2026 Heather Brianne DixonPresident and Chief Operating Sold plan 288 $93.77 $0.0M Form 4
May 21, 2026 Esteban LopezDirector Sold 250 $93.00 $0.0M Form 4
May 19, 2026 Esteban LopezDirector Sold 250 $93.00 $0.0M Form 4
Apr 21, 2026 Cliff Donald BlessingEVP, Chief Development Officer Sold plan 178 $93.61 $0.0M Form 4
Mar 2, 2026 Monica RainesEVP, CCO and Quality Officer Sold plan 224 $102.15 $0.0M Form 4
Feb 25, 2026 Allison R DirkChairman and CEO, Director Sold plan 2,364 $105.36 $0.2M Form 4
Feb 25, 2026 Brian PoffEVP, Chief Financial Officer Sold plan 820 $105.36 $0.1M Form 4
Feb 25, 2026 Darby AndersonEVP, Chief Govt Rel Officer Sold plan 396 $105.36 $0.0M Form 4
Feb 25, 2026 David W. TuckerEVP, Chief Strategy Officer Sold plan 379 $105.36 $0.0M Form 4
Feb 25, 2026 Michael D. WattenbargerEVP, Chief Information Officer Sold plan 300 $105.36 $0.0M Form 4
Feb 25, 2026 Roberton James StevensonEVP, Chief HR Officer Sold plan 284 $105.36 $0.0M Form 4
Feb 25, 2026 Sean GaffneyEVP, Chief Legal Officer Sold plan 442 $105.36 $0.0M Form 4

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY23FY24FY25
Net income is positive ✓ ✓ ✓
Cash from operations is positive ✓ ✓ ✓
Return on assets rose ✓ ✓ ✕
Cash from operations exceeds net income ✓ ✓ ✓
Debt fell relative to assets ✓ ✕ ✓
Current ratio rose ✕ ✓ ✓
Share count didn't rise ✕ ✕ ✕
Gross margin rose ✓ ✓ ✕
Revenue rose relative to assets ✓ ✕ ✕
F-score 7 / 96 / 95 / 9
Accruals ratio −5.1%−3.5%−1.1%
Altman Z'' 4.254.155.50

Similar companies

Each company's latest fiscal year. Fiscal years end in different months, so periods don't line up exactly.

CompanyMarket capGrowthOp. marginFCF marginROICP/EF-score
Addus HomeCare ADUS $2.3B 23.2% 9.7% 7.3% 9.4% 21.3x 5
Lifestance Health LFST $5.0B 13.9% 1.7% 7.7% 1.2% 99.5x 7 Compare →
Tempus AI TEM $13.5M 83.4% −19.9% −18.8% — — 5 Compare →
Sotera Health SHC $5.2B 5.7% — 12.8% 6.7% 31.8x 7 Compare →
CorVel CRVL $4.3B 7.0% — 11.5% — 37.3x — Compare →

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $401M $426M $517M $649M $765M $865M $951M $1.1B $1.2B $1.4B
Gross profit $106M $116M $137M $179M $226M $270M $300M $340M $375M $462M
Operating income $15.5M $25.3M $22.8M $34.8M $44.5M $65.9M $68.7M $91.0M $103M $139M
Interest expense $2.3M $4.5M $5.0M $3.1M $3.2M $5.8M $8.9M $11.1M $7.7M $13.6M
Pretax income $16.2M $21.1M $20.4M $33.2M $41.9M $60.4M $60.2M $81.3M $99.4M $127M
Income tax $4.1M $9.3M $4.1M $7.4M $8.8M $15.3M $14.1M $18.8M $25.8M $31.5M
Net income $12.2M $12.0M $16.4M $25.2M $33.1M $45.1M $46.0M $62.5M $73.6M $95.9M
Diluted EPS $1.07 $1.03 $1.33 $1.77 $2.08 $2.81 $2.84 $3.83 $4.23 $5.22
Diluted shares 0.01B 0.01B 0.01B 0.01B 0.02B 0.02B 0.02B 0.02B 0.02B 0.02B
Cash flow
Cash from operations −$0.7M $52.8M $33.2M $12.0M $109M $39.5M $105M $112M $116M $112M
Capital expenditure $1.7M $3.6M $5.3M $4.6M $6.8M $4.6M $8.3M $9.5M $6.0M $7.7M
Free cash flow −$2.5M $49.2M $27.9M $7.4M $103M $34.8M $96.8M $103M $110M $104M
Depreciation and amortization $6.6M $6.7M $8.6M $10.6M $12.1M $14.5M $14.1M $14.1M $13.5M $16.4M
Stock-based compensation $1.1M $2.6M $4.1M $5.8M $6.0M $9.4M $10.6M $10.3M $11.2M $16.4M
Acquisitions $20.0M $24.4M $62.4M $184M $208M $37.4M $98.3M $110M $354M $0.0M
Share buybacks $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends paid $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Dividends and buybacks $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Balance sheet
Cash and short-term investments $8.0M $53.8M $70.4M $112M $145M $169M $80.0M $64.8M $98.9M $81.6M
Total debt $25.0M $43.0M $17.3M $59.9M $195M $221M $132M $124M $218M $121M
Finance lease liabilities $0.0M $0.0M $0.1M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Current assets $131M $156M $176M $269M $288M $324M $223M $200M $260M $270M
Current liabilities $49.6M $55.1M $61.5M $87.5M $144M $118M $131M $145M $156M $150M
Inventory $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Property and equipment, net $6.6M $7.5M $10.7M $12.2M $19.7M $18.5M $21.2M $24.0M $24.7M $25.0M
Total assets $230M $272M $348M $637M $893M $948M $938M $1.0B $1.4B $1.4B
Total liabilities $72.1M $95.4M $79.6M $161M $374M $373M $305M $318M $442M $352M
Shareholders' equity $155M $170M $269M $476M $519M $574M $634M $707M $971M $1.1B
Margins
Gross margin 26.5% 27.2% 26.5% 27.6% 29.6% 31.2% 31.5% 32.1% 32.5% 32.5%
Operating margin 3.9% 5.9% 4.4% 5.4% 5.8% 7.6% 7.2% 8.6% 8.9% 9.7%
EBITDA margin 5.5% 7.5% 6.1% 7.0% 7.4% 9.3% 8.7% 9.9% 10.1% 10.9%
Net margin 3.0% 2.8% 3.2% 3.9% 4.3% 5.2% 4.8% 5.9% 6.4% 6.7%
FCF margin −0.6% 11.5% 5.4% 1.1% 13.4% 4.0% 10.2% 9.7% 9.6% 7.3%
Returns
Return on capital 7.4% 8.6% 9.7% 8.5% 7.1% 8.3% 8.0% 9.6% 8.2% 9.4%
Return on capital employed 9.6% 12.7% 9.1% 8.3% 6.9% 8.4% 8.4% 10.8% 9.6% 10.9%
Return on equity 8.2% 7.4% 7.5% 6.8% 6.7% 8.3% 7.6% 9.3% 8.8% 9.3%
Return on assets 5.9% 4.8% 5.3% 5.1% 4.3% 4.9% 4.9% 6.4% 6.0% 6.7%
Growth
Revenue growth — 6.3% 21.3% 25.6% 17.9% 13.0% 10.0% 11.3% 9.1% 23.2%
Net income growth 4.6% −1.7% 37.5% 53.6% 31.3% 36.2% 2.0% 35.8% 17.7% 30.3%
EPS growth 2.9% −3.7% 29.1% 33.1% 17.5% 35.1% 1.1% 34.9% 10.4% 23.4%
FCF growth −229.7% — −43.3% −73.4% 1,286.6% −66.0% 177.9% 6.2% 7.4% −6.0%
Share count change 1.4% 2.4% 6.5% 15.1% 12.0% 0.7% 0.7% 0.8% 6.6% 5.8%
Financial health
Net debt / EBITDA 0.8x −0.3x −1.7x −1.1x 0.9x 0.7x 0.6x 0.6x 1.0x 0.3x
Debt / equity 0.2x 0.3x 0.1x 0.1x 0.4x 0.4x 0.2x 0.2x 0.2x 0.1x
Interest coverage 6.6x 5.7x 4.6x 11.2x 14.0x 11.4x 7.7x 8.2x 13.3x 10.2x
Current ratio 2.6x 2.8x 2.9x 3.1x 2.0x 2.8x 1.7x 1.4x 1.7x 1.8x
Quick ratio 2.6x 2.8x 2.9x 3.1x 2.0x 2.8x 1.7x 1.4x 1.7x 1.8x
Capital allocation
Capex / revenue 0.4% 0.9% 1.0% 0.7% 0.9% 0.5% 0.9% 0.9% 0.5% 0.5%
Stock comp / revenue 0.3% 0.6% 0.8% 0.9% 0.8% 1.1% 1.1% 1.0% 1.0% 1.2%
Payouts / FCF — 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Quality scores
Piotroski F-score — 5.0 7.0 5.0 4.0 5.0 6.0 7.0 6.0 5.0
Altman Z'' 6.0 5.9 7.0 5.9 3.4 4.2 4.2 4.3 4.2 5.5
Accruals ratio 6.2% −16.3% −5.4% 2.7% −10.0% 0.6% −6.3% −5.1% −3.5% −1.1%

Source: SEC EDGAR XBRL filings (CIK 0001468328). Data updated October 22, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open